Patents by Inventor Tirtha Chakraborty

Tirtha Chakraborty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
    Publication number: 20180311381
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: October 23, 2017
    Publication date: November 1, 2018
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
  • MODIFIED POLYNUCLEOTIDES FOR ALTERING CELL PHENOTYPE
    Publication number: 20180291335
    Abstract: The present invention relates to compositions, methods and kits using cell phenotype altering polynucleotides, cell phenotype altering primary transcripts and cell phenotype altering mmRNA molecules.
    Type: Application
    Filed: November 16, 2017
    Publication date: October 11, 2018
    Inventors: Stephane Bancel, Antonin de Fougerolles, Susan Whoriskey, Tirtha Chakraborty, Eric Yi-Chun Huang
  • METHODS FOR THERAPEUTIC ADMINISTRATION OF MESSENGER RIBONUCLEIC ACID DRUGS
    Publication number: 20180256628
    Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit AD A or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
    Type: Application
    Filed: October 5, 2016
    Publication date: September 13, 2018
    Inventors: Stephen HOGE, Tirtha CHAKRABORTY, Gilles BESIN, Ruchi JAIN
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
    Publication number: 20180170990
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: July 27, 2017
    Publication date: June 21, 2018
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD, Ron WEISS, Kristy M. WOOD
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
    Publication number: 20180086807
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: February 23, 2017
    Publication date: March 29, 2018
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
  • LONG-LIVED POLYNUCLEOTIDE MOLECULES
    Publication number: 20180086816
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of long-lived polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: May 10, 2017
    Publication date: March 29, 2018
    Inventors: Stephen G. Hoge, Eric Yi-Chun Huang, Tirtha Chakraborty, Sayda M. Elbashir
  • TERMINALLY MODIFIED RNA
    Publication number: 20180000910
    Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
    Type: Application
    Filed: February 10, 2017
    Publication date: January 4, 2018
    Inventors: Tirtha CHAKRABORTY, Stephane BANCEL, Stephen G. HOGE, Atanu ROY, Antonin de FOUGEROLLES, Noubar B. AFEYAN
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
    Publication number: 20180002393
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.
    Type: Application
    Filed: February 6, 2017
    Publication date: January 4, 2018
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
    Publication number: 20170368200
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: February 6, 2017
    Publication date: December 28, 2017
    Inventors: Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
  • MULTIPARAMETRIC NUCLEIC ACID OPTIMIZATION
    Publication number: 20170362627
    Abstract: The present disclosure provides multiparametric codon optimization methods to improve at least a property in a candidate nucleic acid sequence. Such parameters include improving nucleic acid stability (e.g., mRNA stability), increasing translation efficacy in the target tissue, reducing the number of truncated proteins expressed, improving the folding or prevent misfolding of the expressed proteins, reducing toxicity of the expressed products, reducing cell death caused by the expressed products, and increasing or decreasing protein aggregation. After such optimization, the resulting optimized nucleic acid sequence has at least one optimized property with respect to the candidate nucleic acid sequence.
    Type: Application
    Filed: November 4, 2015
    Publication date: December 21, 2017
    Inventors: John van Wicheren REYNDERS, III, Tirtha CHAKRABORTY, Stephen HOGE, Iain James MCFADYEN
  • TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES
    Publication number: 20170362605
    Abstract: The present invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides comprising at least one terminal modification. Described herein are polynucleotides comprising at least one terminal modification, methods, processes, kits and devices using the polynucleotides comprising at least one terminal modification in one or more untranslate regions. Such untranslated regions may be a 5? or 3? untranslated region.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 21, 2017
    Inventor: Tirtha CHAKRABORTY
  • IN VIVO PRODUCTION OF PROTEINS
    Publication number: 20170348436
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: January 11, 2017
    Publication date: December 7, 2017
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • Modified polynucleotides for the production of proteins
    Patent number: 9827332
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: November 28, 2017
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Jeff Lynn Ellsworth, Kenechi Ejebe, Justin Guild, Matthias John, Paul Hatala, Atanu Roy, Jason P. Schrum, Susan Whoriskey, Kristy M. Wood
  • Modified polynucleotides for the production of secreted proteins
    Patent number: 9828416
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: November 28, 2017
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • Modified polynucleotides for the production of biologics and proteins associated with human disease
    Patent number: 9814760
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: November 14, 2017
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • Modified polynucleotides for the production of proteins associated with human disease
    Patent number: 9782462
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 10, 2017
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA
    Publication number: 20170252461
    Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
    Type: Application
    Filed: October 14, 2016
    Publication date: September 7, 2017
    Inventors: Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES
  • TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES
    Publication number: 20170202979
    Abstract: The present invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides comprising at least one terminal modification.
    Type: Application
    Filed: July 17, 2015
    Publication date: July 20, 2017
    Inventors: Tirtha CHAKRABORTY, Stephen G. HOGE
  • Modified polynucleotides encoding hepatitis A virus cellular receptor 2
    Patent number: 9675668
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: June 13, 2017
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey, Ron Weiss
  • Terminally modified RNA
    Patent number: 9597380
    Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: March 21, 2017
    Assignee: ModernaTx, Inc.
    Inventors: Tirtha Chakraborty, Stephane Bancel, Stephen G. Hoge, Atanu Roy, Antonin de Fougerolles, Noubar B. Afeyan